Total Valuation
Anavex Life Sciences has a market cap or net worth of CHF182.98M. The enterprise value is CHF122.28.
Market CapCHF182.98M
Enterprise ValueCHF122.28
Share Statistics
Anavex Life Sciences has ― shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding―
Owned by Insiders1.65%
Owned by Institutions2.29%
Financial Efficiency
Anavex Life Sciences’s return on equity (ROE) is -0.49 and return on invested capital (ROIC) is -54.19%.
Return on Equity (ROE)-0.49
Return on Assets (ROA)-0.45
Return on Invested Capital (ROIC)-54.19%
Return on Capital Employed (ROCE)-0.54
Revenue Per Employee0.00
Profits Per Employee-1.36M
Employee Count34
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Anavex Life Sciences is ―. Anavex Life Sciences’s PEG ratio is -4.29.
PE Ratio―
PS Ratio0.00
PB Ratio8.00
Price to Fair Value8.00
Price to FCF-19.44
Price to Operating Cash Flow-5.48
PEG Ratio-4.29
Income Statement
In the last 12 months, Anavex Life Sciences had revenue of 0.00 and earned -46.38M in profits. Earnings per share was -0.54.
Revenue0.00
Gross Profit0.00
Operating Income-51.41M
Pretax Income-46.38M
Net Income-46.38M
EBITDA-46.38M
Earnings Per Share (EPS)-0.54
Cash Flow
In the last 12 months, operating cash flow was -33.73M and capital expenditures 0.00, giving a free cash flow of -33.73M billion.
Operating Cash Flow-33.73M
Free Cash Flow-33.73M
Free Cash Flow per Share-10.00T>
Dividends & Yields
Anavex Life Sciences pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.35
52-Week Price Change―
50-Day Moving Average―
200-Day Moving Average―
Relative Strength Index (RSI)―
Average Volume (3m)―
Important Dates
Anavex Life Sciences upcoming earnings date is Nov 30, 2026, TBA (Confirmed).
Last Earnings DateJul 30, 2026
Next Earnings DateNov 30, 2026
Ex-Dividend Date―
Financial Position
Anavex Life Sciences as a current ratio of 11.60, with Debt / Equity ratio of 0.00%
Current Ratio11.60
Quick Ratio11.60
Debt to Market Cap0.00
Net Debt to EBITDA2.21
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Anavex Life Sciences has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Anavex Life Sciences EV to EBITDA ratio is -14.16, with an EV/FCF ratio of -16.81.
EV to Sales0.00
EV to EBITDA-14.16
EV to Free Cash Flow-16.81
EV to Operating Cash Flow-16.81
Balance Sheet
Anavex Life Sciences has CHF118.33M in cash and marketable securities with CHF0.00 in debt, giving a net cash position of CHF118.33M billion.
Cash & Marketable SecuritiesCHF118.33M
Total DebtCHF0.00
Net CashCHF118.33M
Net Cash Per ShareCHF10.00T>
Tangible Book Value Per ShareCHF1.11
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Anavex Life Sciences is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―